Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Reduction of risk of NSAID-associated gastric ulcers
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. Duration typically 4-8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **NSAID-Induced Ulcers (Prevention/Treatment):** 40 mg orally once daily.
* **Hypersecretory Conditions:** Start with 40 mg orally or intravenously twice daily. Doses may be increased as needed. Maximum dose typically 120 mg intravenously daily or 240 mg orally daily divided into two doses.
## Pediatric Dosing
* **GERD (12 years and older):** 40 mg orally once daily.
* **Erosive Esophagitis (12 years and older):** 40 mg orally once daily for up to 8 weeks.
* **Erosive Esophagitis (5 years to <12 years):** 20-40 mg orally once daily. The specific dose depends on weight and severity. (Weight-based dosing: 1.0-2.0 mg/kg/day, not to exceed 40 mg/day).
* **Erosive Esophagitis (<5 years):** Dosing is not well-established for this age group and should be based on available data and clinical judgment.
## Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, dizziness, and flatulence. Long-term use may be associated with an increased risk of *Clostridium difficile* infection, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Certain Antiretrovirals (e.g., rilpivirine, atazanavir):** Pantoprazole can decrease absorption due to increased gastric pH. Separate administration or avoid.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Monitor methotrexate levels and consider dose reduction or temporary discontinuation of pantoprazole.
* **Clopidogrel:** Pantoprazole may decrease the antiplatelet effect of clopidogrel. Consider the risks and benefits, and monitor for cardiovascular events. Some evidence suggests the interaction may be less significant with pantoprazole compared to omeprazole.
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile*-associated diarrhea.
* Monitor serum magnesium levels, especially with prolonged use (>1 year) or concurrent diuretic use.
* Consider monitoring bone mineral density in patients at risk for osteoporosis.
* Monitor for signs of B12 deficiency with prolonged therapy.
## Clinical Pearls
* Intravenous pantoprazole can be administered as an infusion or bolus. Reconstitute according to manufacturer instructions.
* Oral formulations should be taken 30-60 minutes before a meal for optimal efficacy.
* For patients unable to swallow whole tablets, pantoprazole delayed-release oral suspension or sprinkle capsules are available.
**Disclaimer:** This information is a summary and not exhaustive. Always consult the official prescribing information and relevant clinical guidelines for the most current and complete drug information before making any clinical decisions.
